In total, tumor-informed mutational analyses of cfDNA were performed in 309 samples from patients with RAS/BRAF mutant tumors, while DELFI-TF analyses were performed in 689 samples from patients in both RAS/BRAF mutant and wild-type tumors (Supplementary Fig. 2). This evidence concerns the gene TF and neoplasm.